What Changed in the Guideline
Before the numbers make sense, the guideline changes underneath them do.
The 2026 ACC/AHA/multisociety dyslipidemia guideline, released in March, made several structural changes to how cardiovascular risk is assessed. It replaced the older pooled cohort equations with the PREVENT equations. It widened the age range for risk estimation from 40 to 75 years to 30 to 79 years. It added 30-year risk estimation alongside the traditional 10-year horizon. It lowered the thresholds defining risk categories, setting low 10-year risk below 3 percent and high risk at 10 percent or above. It also recommends measuring lipoprotein(a) at least once to identify inherited risk.
Each of those changes pulls in a different direction. The PREVENT equations generally estimate lower short-term risk than the older calculator, which by itself would shrink the treated population. The wider age band, longer horizon, and lower thresholds push the other way, and they push harder.
What the Three Analyses Estimated
Three separate analyses using nationally representative survey data have now modeled the effect, and the headline figure comes from the largest.
Researchers at the University of Pittsburgh analyzed National Health and Nutrition Examination Survey data from 2017 to 2023, covering 4,366 nonpregnant participants representing roughly 154.5 million U.S. adults aged 30 to 79 without existing cardiovascular disease. Under the 2026 guideline, 56.6 percent of that population, about 87.5 million people, would be eligible for primary prevention statin therapy. That includes 21.5 million adults who were not eligible under the 2018 guideline.
A second analysis, led by Allison Peng, MD, of the Ciccarone Center for the Prevention of Cardiovascular Disease at Johns Hopkins, estimated that roughly 22 percent of U.S. adults would be reclassified, primarily because more people fall into the borderline 10-year risk category, as Medscape reported.
A third analysis, drawing on NHANES data from 2011 to 2023, found that more than 60 percent of adults aged 30 to 79 in the primary prevention population have a statin indication under the new guideline. That study attributed the expansion almost entirely to new Class 2a recommendations covering adults with borderline or low 10-year risk, and reported that only 27 percent of eligible adults were actually taking lipid-lowering therapy.
Who Moves Into the Recommended Group
The composition of the newly eligible group is more informative than the total.
People newly recommended for statins under the 2026 guideline are younger and at lower short-term risk than those already eligible. Their mean predicted 10-year cardiovascular risk is 3.1 percent, compared with 6.1 percent among adults eligible under both the 2018 and 2026 guidelines.
Age remains the dominant driver of eligibility. More than 93 percent of adults aged 70 to 79 and 85 percent of those aged 60 to 69 are candidates for primary prevention therapy. Among adults in their thirties, the figure is about 11 percent, which is small in proportion and represents a group that under previous guidance was generally not assessed at all.
Not everyone in the eligible population needs a risk calculation. Roughly 9.6 percent qualify regardless of estimated risk because of LDL cholesterol at or above 190 mg/dL, diabetes or chronic kidney disease. About 17.8 percent already report taking statins. The remaining 68 percent fall into the group where a risk estimate guides the decision.
The Nuance the Headline Number Hides
A single figure of 87.5 million invites a conclusion the data do not fully support, and the corrective is in the same body of work.
Among adults aged 40 to 79, the proportion eligible for lipid-lowering therapy was nearly unchanged, at 49.6 percent under the 2026 guideline against 49.4 percent previously. The expansion is concentrated in the newly assessed 30 to 39 age band and in reclassification within borderline risk categories. That pattern describes a change in who is recommended for treatment more than a wholesale increase in how many.
The strength of the recommendation also differs. Much of the expansion comes through Class 2a recommendations, which in guideline language means treatment is reasonable, a weaker designation than Class 1, which means it is recommended. That distinction is invisible in an eligibility count and central to a clinical conversation.
The most important limitation is what these analyses did not do. They modeled how many people meet criteria. None of them tested whether treating the newly eligible group prevents heart attacks or strokes, whether the benefit in a 34-year-old with 3 percent 10-year risk justifies decades of therapy, or what the cost and adherence consequences would be. Those are empirical questions these papers do not answer.
What Patients Should Do With This
Eligibility is not a prescription, and the gap between the two is where the actual decision lives.
If you are between 30 and 79 without known cardiovascular disease and have not had a lipid panel and risk assessment recently, that is the concrete step this research supports. The new calculator requires inputs many people do not have on hand, including current lipid values, blood pressure and kidney function.
If a clinician raises statin therapy and your 10-year risk is low, ask which class of recommendation applies, what the 30-year estimate looks like, and what the expected absolute benefit is over a defined period. A relative risk reduction sounds larger than a small absolute one, and both are worth hearing.
Ask about lipoprotein(a) testing, which the guideline now recommends at least once. It is a one-time measurement that can identify inherited risk not captured by standard panels.
Lifestyle guidance did not change and applies regardless of eligibility. As one of the study authors noted, physicians have long recommended a healthy diet, exercise, and smoking cessation to all patients irrespective of cholesterol levels and will continue to do so.
The open question now is how prescribing shifts actually, given that only about 27 percent of eligible adults were taking lipid-lowering therapy under the prior standard. MedicalDaily will report outcomes research on the newly eligible population and any payer coverage changes that follow.
Frequently Asked Questions
How many adults are now statin-eligible? An estimated 56.6 percent of U.S. adults aged 30 to 79 without cardiovascular disease, about 87.5 million people, including 21.5 million newly eligible.
What changed in the guideline? It uses the PREVENT equations, extends risk assessment to ages 30 to 79, adds 30-year risk estimation, lowers risk category thresholds and recommends measuring lipoprotein(a) once.
Who are the newly eligible people? Mostly younger adults at lower short-term risk, with a mean 10-year risk of 3.1 percent compared with 6.1 percent among those already eligible.
Does eligibility mean I should take a statin? No. Eligibility means the criteria are met. Much of the expansion falls under Class 2a recommendations, meaning treatment is reasonable rather than strongly recommended.
Did these studies show statins help this new group? No. They estimated eligibility only. None tested clinical outcomes in the newly eligible population.
What is lipoprotein(a) and why test it? It is a lipid particle influenced largely by inherited factors and not captured on standard panels. The guideline recommends measuring it at least once.
What should I do next? If you are 30 to 79 without known cardiovascular disease, ask about a lipid panel and an updated risk assessment, and discuss absolute benefit before deciding.
